Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Phase I/II Study of CT-P13 vs Remicade in Rheumatoid Arthritis
jRCT2080221580Phase 2
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of infliximab-dyyb in rheumatoid arthritis (RA) (2 arms), sponsored by Nippon Kayaku Co., Ltd.
02
Drugs
infliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080221580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221580.